---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009485"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-05T00:16:55.358847+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enveric issues 228,690 shares for waiver of variable-rate limitation, enabling ATM facility

## Summary
- Issued 228,690 common shares at $1.41/share to institutional investors; no proceeds to Enveric.
- Investors permanently waive variable rate transaction limitation from Dec 28, 2023 inducement letters.
- Waiver allows Enveric to utilize its 'at the market' offering facility with Canaccord Genuity.
- Closing expected March 12, 2024; shares represent ~4.2% of outstanding (5.4M pre-offering).

## SEC filing metadata
- accession: 0001493152-24-009485
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224009485/0001493152-24-009485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224009485/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009485
- JSON: https://secwatch.observer/filing/0001493152-24-009485.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009485.txt

## Key facts
- Material Agreements
  Enveric Biosciences, Inc. entered into Purchase Agreement with certain institutional investors (effective 2024-03-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2024-03-08
  source text: On March 8, 2024, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into a series of common stock purchase agreements (the “Purchase Agreement”) for the issuance in a registered direct offering of 228,690 shares of the Company’s common stock, par value $0.01 per share (the “Shares”), to certain institutional investors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315224009485/0001493152-24-009485-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.